Importantly, VEGF-Ax possesses anti-angiogenic activity opposite that of VEGF-A, and its expression is depleted in colon adenocarcinoma, suggesting that this translational readthrough event is manipulated by cancer cells to their advantage. This evidence concerns the gene VEGFA and cancer.